Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus, Systemic Lupus Erythematosus research hub

Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus

This study is testing a new medicine, BMS-986326, for people aged 18 and over with lupus, including discoid, subacute cutaneous, or systemic lupus. It aims to see how different doses affect the body and identify common side effects, helping researchers understand if it could be a future treatment.